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the relationship of circulating 
fibroblast growth factor 21 levels 
with pericardial fat: The Multi-
Ethnic Study of Atherosclerosis
Arsenios Magdas1,2, Jingzhong Ding3, Robyn L. McClelland4, Matthew A. Allison5, 
Philip J. Barter1, Kerry-Anne Rye1 & Kwok Leung ong1*
Previous small studies have reported an association between circulating fibroblast growth factor 21 
(FGF21) levels and pericardial fat volume in post-menopausal women and high cardiovascular disease 
(CVD) risk patients. In this study, we investigated the relationship of FGF21 levels with pericardial fat 
volume in participants free of clinical CVD at baseline. We analysed data from 5765 men and women 
from the Multi-Ethnic Study of Atherosclerosis (MESA) with both pericardial fat volume and plasma 
FGF21 levels measured at baseline. 4746 participants had pericardial fat volume measured in at least 
one follow-up exam. After adjusting for confounding factors, ln-transformed FGF21 levels were 
positively associated with pericardial fat volume at baseline (β = 0.055, p < 0.001). When assessing 
change in pericardial fat volume over a mean duration of 3.0 years using a linear mixed-effects model, 
higher baseline FGF21 levels were associated with higher pericardial fat volume at baseline (2.381 cm3 
larger in pericardial fat volume per one SD increase in ln-transformed FGF21 levels), but less pericardial 
fat accumulation over time (0.191 cm3/year lower per one SD increase in ln-transformed FGF21 levels). 
Cross-sectionally, higher plasma FGF21 levels were significantly associated with higher pericardial 
fat volume, independent of traditional CVD risk factors and inflammatory markers. However, higher 
FGF21 levels tended to be associated with less pericardial fat accumulation over time. Nevertheless, 
such change in pericardial fat volume is very modest and could be due to measurement error. Further 
studies are needed to elucidate the longitudinal relationship of baseline FGF21 levels with pericardial 
fat accumulation.
Pericardial fat is located between the external surface of the parietal pericardium and the internal surface of the 
mediastinum1. It includes epicardial fat and paracardial fat. A recent study has shown a significant association 
between excessive pericardial fat volume, especially fat in the atrioventricular groove, and coronary artery dis-
ease2. Additionally, a previous Multi-Ethnic Study of Atherosclerosis (MESA) has reported the association of per-
icardial fat with risk of coronary heart disease (CHD), independent of classical cardiovascular risk factors such as 
body mass index (BMI), blood lipids, fasting glucose, and C-reactive protein (CRP) levels3. A more recent study 
of the MESA cohort reported a significant association between pericardial fat and poorer CVD prognosis includ-
ing higher annualised risk of all cause death, heart failure, all-cause CVD, coronary heart disease and stroke4.
FGF21 regulates glucose and lipid metabolism in multiple organs such as the liver, heart, skeletal muscle, pan-
creas and others5–7. Several recent animal studies have shed light on the beneficial effects of FGF21 administration 
on glucose and lipid metabolism, including decreased body weight and improved lipid profiles5–7. However, in 
humans, circulating FGF21 levels are often elevated in different pathophysiological conditions such as metabolic 
syndrome, obesity, dyslipidemia, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease and coronary 
artery disease5. There is strong evidence suggesting a significant association between elevated serum FGF21 levels 
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and the development of atherosclerosis, myocardial ischemia, coronary heart disease, cardiac hypertrophy, and 
diabetic cardiomyopathy6,8.
Small clinical studies have suggested a positive association of circulating FGF21 levels with epicardial or peri-
cardial fat volume in post-menopausal women and people at high CVD risk9,10. However, it is not known whether 
such an association is relevant to men and healthy people, and whether there are any sex or racial/ethnic differ-
ences in the association of plasma FGF21 levels with pericardial fat volume. Therefore, in the present study, the 
relationship of FGF21 levels and pericardial fat was investigated using a large-scale well-established cohort of 
participants, free of clinically apparent CVD.
Materials and Methods
Participants. The MESA is a cohort of 6814 adult men and women recruited from six United States commu-
nities (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles County, CA; New York, NY, and St. Paul, 
MN) between July 2000 and August 2002. At baseline exam 1, all participants were aged between 45–84 years, 
from one of four major racial/ethnic groups (Caucasian, African American, Hispanic American and Chinese 
American) and had no clinical evidence of CVD. The participants underwent four additional follow up assess-
ments over a period of 10 years (exams 2, 3, 4, and 5 in 2002–2004, 2004–2005, 2005–2008 and 2010–2012, 
respectively). Informed written consent was obtained from all participants and the study was approved by the 
institutional review boards at all participating centres (Johns Hopkins Medicine Institutional Review Board, Wake 
Forest University Health Sciences Institutional Review Board, Northwestern University Institutional Review 
Board, University of California Los Angeles Institutional Review Board, Columbia University Medical Center 
Institutional Review Board, University of Minnesota Institutional Review Board, University of Washington 
Institutional Review Board, and University of Vermont Institutional Review Board). The analysis of FGF21 levels 
was also approved by the University of New South Wales Sydney Human Research Advisory Panel. The study was 
conducted in adherence with all principles of the Declaration of Helsinki. The objectives, design and protocol of 
the study have been described previously11.
Of the 6814 participants at baseline, data on pericardial fat volume at the baseline exam were available on 6785 
participants, 5765 of whom also plasma FGF21 levels measured.
Pericardial fat measurement. Pericardial fat measurements were obtained from thoracic computed 
tomography (CT) scans. Three field centres used an electro-beam CT scanner while the other 3 field centres 
utilised a multidetector row helical CT scanner. The resulting CT scans were analysed for pericardial fat volume 
as described previously3. In brief, the CT slices within 15 mm above and 30 mm below the superior extent of 
the left main coronary artery were analysed by three different experienced CT analysts. This region of the heart 
was selected as it includes the pericardial fat located around all the main proximal coronary arteries (left main 
coronary, left anterior descending, right coronary, and circumflex arteries). The volume analysis software (GE 
HealthCare, Waukesha, WI) was used to discern fat from other tissues according to a threshold of −190 to −30 
Hounsfield units. Pericardial fat volume was defined as the sum of all voxels containing fat. This measure of peri-
cardial fat volume was previously found to be highly correlated with total volume of pericardial fat volume12. CT 
scans from a random sample of 80 MESA participants were reread and the intraclass correlation coefficients of 
intra-reader and inter-reader reliability were 0.99 and 0.89, respectively, for pericardial fat3.
FGF21 measurement. Venous blood samples were collected after a 12-hour fast using standardized 
venipuncture procedures. Plasma FGF21 levels were measured by enzyme-linked immunosorbent assay kits 
(Antibody and Immunoassay Services, University of Hong Kong, Hong Kong) at baseline13,14. Briefly, plasma 
(60 μl) was diluted 1:1 (v/v) with assay diluent and analyzed together with quality controls according to manu-
facturer’s instructions. The intra-assay and inter-assay coefficients of variation were < 10%. Patient identity was 
masked for all samples analysed.
Other variables of interest. Standardized questionnaires were used to ascertain information regard-
ing participant age, gender, smoking, education, alcohol use, race/ethnicity, physical activity, medical history 
and medication. Education level was defined as high school, less than high school and more than high school. 
Cigarette smoking was defined as never, former, and current smoking. Physical activity was summarized as the 
total number of reported hours of moderate and vigorous activities per week, multiplied by metabolic equivalent 
level as previously described15.
Height and weight measurements were taken with participants wearing light clothing and no shoes. BMI 
was calculated as the weight (in kilograms) divided by height (in meters squared). Hip and waist circumferences 
were obtained using standard flexible tape measures. A Dinamap model Pro 100 automated oscillometric sphyg-
momanometer (Critikon) was used to take three measurements of sitting resting blood pressure. The average of 
the last two blood pressure readings was used for analysis. Hypertension was defined as use of antihypertensive 
medications, blood pressure ≥140/90 mm Hg or previous diagnosis of hypertension. Diabetes was defined as use 
of glucose-lowering medications or fasting glucose ≥126 mg/dL. Estimated glomerular filtration rate (eGFR) 
was calculated using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation16. The 
homeostasis model assessment index of insulin resistance (HOMA-IR) was calculated according to the updated 
computer model as described previously17. The lipid profile, and CRP and interleukin-6 (IL-6) levels were meas-
ured as previously described18,19.
Statistical analysis. Data analysis was performed using SPSS 24 (IBM, Armonk, NY) or STATA 14.0 
(StataCorp, College Station, TX). Data were presented as mean (SD) or percentage (number). For variables with 
a skewed distribution, data were presented as median (interquartile range). Distributions of demographic data, 
CVD risk factors, and pericardial fat volume at baseline were compared across FGF21 quartiles among all the 
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participants. Age, sex, BMI, race/ethnicity and other variables that showed an increasing or decreasing trend 
with FGF21 levels after adjusting for age, sex, and race/ethnicity (p < 0.1) were used as covariates in subsequent 
multiple regression analyses. A multivariable linear regression model was used to investigate the cross-sectional 
association of plasma FGF21 levels with pericardial fat volume using robust standard error estimation after 
adjusting for age, sex, and ethnicity. In model 1, data were adjusted for demographic, socioeconomic and lifestyle 
factors, including age, sex, race/ethnicity, education, smoking, pack-years of smoking, current alcohol use and 
physical activity. In model 2, data were further adjusted for established CVD risk, including BMI, diabetes, hyper-
tension, HOMA-IR, high-density lipoprotein (HDL) cholesterol, triglycerides, eGFR, and use of lipid-lowering 
medication, which have been found to correlate with FGF21 levels in previous studies5,9,10,13,14. As FGF21 has 
anti-inflammatory effects8 and pericardial fat can secrete pro-inflammatory cytokines1, data were further adjusted 
for circulating inflammatory biomarkers, including CRP and IL-6 in model 3, in order to assess whether these 
inflammatory biomarkers can mediate the association.
No multi-collinearity issue was detected as assessed by the variance inflation factors (VIF). All VIF were < 3. 
The non-linear relationship of FGF21 levels with pericardial fat volume at baseline was assessed using regression 
splines. In this analysis, no non-linear relationship was found between FGF21 levels and pericardial fat volume 
at baseline.
Although participants attended up to four additional follow-up visits over a 10-year period, pericardial fat 
volume was not measured in exam 5. Pericardial fat volume was measured in 4515 out of the 5765 participants 
(78.3%) at either exam 2 or 3, and in 921 participants (16.0%) at exam 4. Therefore, a total of 4056 out of the 5765 
participants (70.4%) had pericardial fat volume measured at only one follow-up exam, either at exam 2, 3, or 4. 
Only 690 (12.0%) participants had pericardial fat volume measured at two follow-up exams. We assessed the 
relationship of baseline FGF21 levels with longitudinal change in pericardial fat volume using a standard linear 
mixed-effects model20 among all participants, utilizing data on pericardial fat volume measured at all follow-up 
exams. In the linear mixed-effects model, we used random intercepts (representing baseline pericardial fat vol-
ume for each participant) and random slope (representing the change in pericardial fat volume per year) with 
adjustment for fixed effect of the same set of covariates as in the cross-sectional analysis. The linearity assumption 
was assessed by the inspection of diagnostic residual plots.
In all the analyses, we assessed whether there was any sex or racial/ethnic interaction, and p for interaction 
was estimated by including the interaction term in the regression models in the full sample after adjusting for the 
main effects of the covariates. In all regression analyses, replacement of BMI by waist-to-hip ratio and height in 
the adjustment model made little difference to the results (data not shown). A two-tailed p < 0.05 was considered 
statistically significant.
Results
Participant characteristics. The characteristics of the 5765 participants according to the quartiles of 
plasma FGF21 levels at baseline are shown in Table 1. Participants with higher plasma FGF21 levels were more 
likely to be older, female, Caucasian or Hispanic American, and current smoker, with lower education level. 
Additionally, participants with higher plasma FGF21 levels tended to have lower height, physical activity, HDL 
cholesterol and eGFR, but higher BMI, waist-to-hip ratio, triglycerides, HOMA-IR, IL-6 and CRP levels. They 
also had higher prevalence of diabetes and hypertension and were more likely to take lipid-lowering medications.
Association of FGF21 and pericardial fat volume at baseline. Cross-sectionally, FGF21 levels corre-
lated positively with pericardial fat volume (Spearman correlation coefficient = 0.269, p < 0.001) and participants 
with higher plasma FGF21 levels were more likely to have larger pericardial fat volume (Table 1). In multivariable 
linear regression analysis, higher plasma FGF21 levels were significantly associated with larger pericardial fat 
volume at baseline after adjusting for demographic, socioeconomic and lifestyle factors, although the association 
was modest (Model 1, Table 2). Further adjustment for CVD risk factors attenuated the association, which still 
remained statistically significant (Model 2, Table 2). Further adjusting for inflammatory biomarkers still resulted 
in a significant association between plasma FGF21 levels and pericardial fat volume (Model 3, Table 2). In addi-
tion, there was a significant interaction by sex (p for interaction < 0.001), in which the association was more pro-
nounced in men than in women (β = 0.062 and 0.054 respectively). However, there was no significant interaction 
by race/ethnicity (p for interaction = 0.089).
Association of baseline FGF21 levels with change in pericardial fat volume. Among 5765 partic-
ipants, 4746 participants had pericardial fat volume measured at least one follow-up exam with mean duration 
of 3.0 years with a range of 1.0–6.8 years. Table 3 shows the results on the association of baseline FGF21 levels 
with rate of change in pericardial fat volume using a linear mixed-effects model. Higher baseline FGF21 levels 
were associated with higher pericardial fat volume at baseline, which remained significant after adjusting for 
demographic, socioeconomic and lifestyle factors, CVD risk factors, and inflammatory biomarkers (2.381 cm3 
larger in pericardial fat volume per one SD increase in ln-transformed FGF21 levels). Moreover, a higher baseline 
ln-transformed FGF21 levels were significantly associated with modestly less pericardial fat accumulation over 
time (0.191 cm3/year lower per one SD increase in ln-transformed FGF21 levels).
Discussion
In this present study, elevated circulating FGF21 levels were significantly associated with elevated pericardial fat 
volume cross-sectionally and in a multi-ethnic cohort of adults without a history of clinical cardiovascular dis-
ease. The association tended to be stronger in men than in women. When analyzing the change in pericardial fat 
volume over time using linear mixed-effects model, higher baseline FGF21 levels were found to be associated with 
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less pericardial fat accumulation over time. However, it should be noted that the association of FGF21 levels with 
pericardial fat volume and its accumulation over time is modest only and may have limited clinical significance.
FGF21 shows beneficial effects in animal and clinical studies. FGF21 administration can improve glucose and 
lipid metabolism, including a decrease in body weight and an improvement in lipid profiles in obese and diabetic 
Characteristics n
FGF21 level, pg/mL
P valueQuartile 1 Quartile 2 Quartile 3 Quartile 4
n 5765 1441 1443 1440 1441
Age, years 5765 60.3 ± 10.2 62.6 ± 10.1 63.6 ± 10.1 64.2 ± 10.1 <0.001
Women, n (%) 5765 698 (48.4) 716 (49.6) 788 (54.7) 805 (55.9) <0.001
Race/ethnicity, n (%) 5765 <0.001
Caucasian 2150 511 (35.5) 530 (36.7) 547 (38.0) 562 (39.0)
African American 1661 478 (33.2) 431 (29.9) 382 (26.5) 370 (25.7)
Hispanic American 1256 253 (17.6) 293 (20.3) 343 (23.8) 367 (25.5)
Chinese American 698 199 (13.8) 189 (13.1) 168 (11.7) 142 (9.9)
Education, n (%) 5744 <0.001
<High school 1048 208 (14.5) 248 (17.2) 292 (20.4) 300 (20.9)
High school 2408 544 (37.9) 597 (41.4) 621 (43.4) 646 (44.9)
>High school 2288 682 (47.6) 596 (41.4) 518 (36.2) 492 (34.2)
BMI, kg/m2 5765 27.2 ± 5.0 27.8 ± 5.1 28.9 ± 5.7 29.4 ± 5.7 <0.001
Waist-to-hip ratio 5765 0.91 ± 0.08 0.93 ± 0.08 0.94 ± 0.08 0.95 ± 0.08 <0.001
Height, cm 5765 167.4 ± 9.6 166.9 ± 10.0 165.7 ± 10.4 165.2 ± 10.0 <0.001
Smoking, n (%) 5745
Never 2889 764 (53.2) 725 (50.3) 713 (49.8) 687 (47.8) 0.009
Former 2128 514 (35.8) 548 (38.0) 533 (37.2) 533 (37.1)
Current 728 157 (10.9) 168 (11.7) 185 (12.9) 218 (15.2)
Pack-years of smoking 5683 8.8 ± 16.4 11.3 ± 20.8 11.6 ± 20.6 13.5 ± 23.7 <0.001
Current alcohol use, n (%) 5720 787 (55.2) 826 (57.6) 773 (54.2) 762 (53.1) 0.089
Physical activity (MET-hours/week) 5747 102.7 ± 94.2 98.6 ± 101.4 87.9 ± 92.2 89.0 ± 98.0 <0.001
Diabetes, n (%) 5755 118 (8.2) 173 (12.0) 198 (13.8) 249 (17.3) <0.001
Hypertension, n (%) 5765 518 (35.9) 645 (44.7) 677 (47.0) 781 (54.2) <0.001
Lipid-lowering medication, n (%) 5753 198 (13.8) 243 (16.9) 234 (16.3) 292 (20.3) <0.001
LDL cholesterol, mg/dL 5686 117.0 ± 31.3 117.9 ± 31.8 117.4 ± 30.3 116.3 ± 32.7 0.563
HDL cholesterol, mg/dL 5755 53.4 ± 15.4 51.7 ± 14.9 50.2 ± 14.6 48.4 ± 14.1 <0.001
Triglycerides, mg/dL* 5758 89 (64–125) 105 (78–151) 121 (84–170) 136 (92–199) <0.001
HOMA-IR* 5739 0.80 (0.59–1.14) 0.89 (0.64–1.30) 0.97 (0.71–1.42) 1.12 (0.75–1.62) <0.001
IL-6, pg/mL* 5620 0.98 (0.67–1.56) 1.17 (0.75–1.84) 1.29 (0.85–2.00) 1.49 (0.96–2.29) <0.001
CRP, mg/L* 5732 1.40 (0.62–3.20) 1.68 (0.83–4.00) 2.10 (0.91–4.45) 2.57 (1.12–5.36) <0.001
eGFR, mL/min/1.73 m2 5755 80.5 ± 15.1 78.3 ± 15.5 77.2 ± 16.1 74.0 ± 17.9 <0.001
Pericardial fat at baseline volume, cm3 5765 65.5 ± 35.9 75.9 ± 39.2 86.0 ± 43.4 90.9 ± 43.6 <0.001
Table 1. Baseline characteristics of participants (n = 5765). Data are expressed as mean ± SD, or n (%), or 
median (interquartile range). FGF21 quartiles 1, 2, 3, and 4 were defined as FGF21 levels of ≤81.2, 81.3–146.1, 
146.2–245.4, and ≥245.5 pg/mL. Unadjusted p values were estimated by ANOVA for continuous variables and 
chi-square test for categorical variables respectively. *P values were estimated using ln-transformed data.
Model β P value
1 0.180 <0.001
2 0.061 <0.001
3 0.055 <0.001
Men 0.062 <0.001
Women 0.054 <0.001
Table 2. Association of ln-transformed FGF21 levels with pericardial fat volume at baseline. Regression 
coefficient (β) was estimated with SD as analytic unit, i.e. number of SD (41.8 cm3) difference in pericardial 
fat volume associated with a change of one SD (1.35) in ln-transformed FGF21 level). Model 1: Adjusted for 
age, sex, race/ethnicity, education, smoking, pack-years of smoking, current alcohol use and physical activity. 
Model 2: Further adjusted for BMI, diabetes, hypertension, ln-transformed HOMA-IR, HDL cholesterol, 
ln-transformed triglycerides, eGFR, and use of lipid-lowering medication. Model 3: Further adjusted for ln-
transformed CRP and ln-transformed IL-6. FGF21 indicates fibroblast growth factor 21.
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mice7. Furthermore, FGF21 also shows cardioprotective properties, such as lipid-lowering, anti-inflammatory 
and antioxidant effects in cell culture and animal studies8. In fact, FGF21 also exerts a cardioprotective effect post 
myocardial infarction through the activation of an adiponectin-dependent pathway21. In human clinical trials, 
administration of FGF21 analogs can reduce body weight and improve lipid profile in obese/overweight type 2 
diabetic subjects22,23.
Despite the cardioprotective effect of FGF21, circulating FGF21 levels are often elevated in different metabolic 
disorders5. In human studies, circulating FGF21 levels correlate with BMI24 and are elevated in rodents with 
diet-induced obesity25. The elevation in FGF21 levels in these conditions, and in people with elevated pericardial 
fat volume in the present study, could be a compensatory protective response to the underlying metabolic stress, 
or due to FGF21 resistance25, in which impaired interactions of FGF21 with its receptor and downregulation of 
downstream signaling pathways requires supraphysiological doses of FGF21 to achieve its protective physiolog-
ical function. In fact, it has been reported that epicardial adipose tissue can express FGF21 and the expression is 
increased in response to surgery-related inflammation and insulin resistance after cardiac surgery26.
The present study supports a significant cross-sectional association between FGF21 levels and pericardial fat 
volume. In a recent case-control study of 86 post-menopausal women, serum FGF21 levels were positively and 
significantly correlated with epicardial fat thickness in the obese women9. In that study, among different clinical 
and biochemical parameters including BMI, LDL cholesterol, HDL cholesterol, CRP and HOMA-IR, epicardial 
fat showed the strongest association with serum FGF21 levels9. In another recent cross-sectional study of 60 
patients with coronary artery disease and 129 BMI-matched controls, higher serum FGF21 levels were inde-
pendently associated with pericardial fat volume after adjusting for age, sex, BMI, triglycerides and HOMA-IR10. 
However, these studies have the limitation of small sample size and cross-sectional study design. In the present 
study, FGF21 levels were found to be associated with pericardial fat volume in a much larger, ethnically diverse 
population, even after adjusting for more CVD risk factors, including the pro-inflammatory markers, CRP and 
IL-6.
Previous studies using data from the MESA have reported the association of pericardial fat with coronary 
heart disease and poorer CVD outcomes3,4. In a recent study in mice, plasma FGF21 levels were reported to be an 
early predictive biomarker for the development of CVD risk factors such as insulin resistance, metabolic distur-
bance and cardiac FGF21 resistance27. Therefore, it is possible that elevated plasma FGF21 levels may predict per-
icardial fat accumulation, which is a well-established CVD risk factor. Moreover, in two small proof-of-concept 
trials, administration of synthetic FGF21 analogs decreased body weight and improved the lipid profile in obese\
overweight patients with type 2 diabetes22,23. Therefore, it would be interesting to investigate whether FGF21 
levels has a causal effect on pericardial fat accumulation. However, in the present study, we found that elevated 
plasma FGF21 levels were associated with less pericardial fat accumulation over time. Nevertheless, interpretation 
should be cautious as the change in pericardial fat volume was very modest and may have limited clinical signif-
icance. Moreover, we could not exclude the possibility that the findings on the changes in pericardial fat volume 
could be false positive due to measurement error or the phenomenon of regression to the mean28.
The present study suggests a possible sex difference in the association between FGF21 levels and pericardial fat 
volume at baseline. In previous studies, pericardial fat volume was found to be lower in women, than in men29,30. 
In a recent rat study, hepatic FGF21 expression levels were up-regulated by a chronic high-fat, high-fructose 
diet in male rats, but not in female rats due to suppression of FGF21 resistance by estrogen31. Further studies are 
needed to investigate whether estrogen may affect the expression and function of FGF21 in pericardial fat.
The present study has several strengths. Compared to previous studies on the relationship of FGF21 levels with 
pericardial fat or epicardial fat, the finding from the present study should be more robust due to its large sample 
size and ethnically diverse population. The present study also takes the advantage of a large well-characterised 
sample of participants apparently free of clinical CVD at the time of recruitment and the associated good quality 
data. There are also some limitations in this study. The major limitation is that the two components of pericar-
dial fat: paracardial fat and epicardial fat, have not been separately assessed. Recent clinical evidence suggests 
that epicardial fat plays a more prominent role in CVD and its risk factors such as insulin resistance, metabolic 
syndrome and subclinical atherosclerosis, compared with pericardial fat1. However, to distinguish epicardial fat 
from paracardial fat, one must identify the pericardium which is often difficult to visualise, especially in lean 
individuals32. Moreover, pericardial fat volume was only measured in a sub-cohort in exams 2, 3 and 4, in which 
Model Intercept Slope
1 7.588 (0.503)† −0.184 (0.080)*
2 2.631 (0.432)† −0.192 (0.081)*
3 2.381 (0.437)† −0.191 (0.082)*
Table 3. Association of baseline FGF21 levels with rate of change in pericardial fat volume (n = 5765). The 
intercept estimate represents the regression coefficient (SE) for the association of FGF21 levels with pericardial 
fat volume at baseline. The slope estimate represents the difference (SE) in the rate of change in pericardial 
fat volume (cm3) per year per unit increment in FGF21. Data are expressed as per SD (1.35) increase in ln-
transformed levels. Model 1: Adjusted for age, sex, race/ethnicity, education, smoking, pack-years of smoking, 
current alcohol use and physical activity. Model 2: Further adjusted for BMI, diabetes, hypertension, ln-
transformed HOMA-IR, HDL cholesterol, ln-transformed triglycerides, eGFR, and use of lipid-lowering 
medication. Model 3: Further adjusted for ln-transformed CRP and ln-transformed IL-6. *P < 0.05 and 
†P < 0.001.
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the mean duration between the baseline measurement and the last follow-up measurement was about 3 years and 
the changes in pericardial fat volume were small, which may lead to the modest association observed in this study. 
Another major limitation is that FGF21 levels were not measured at follow-up visits, thus it was not possible to 
assess how FGF21 levels changed relative to pericardial fat volume, and whether pericardial fat volume at baseline 
can predict change in FGF21 levels.
In conclusion, higher plasma FGF21 levels at baseline were associated with higher pericardial fat volume at 
baseline. Higher FGF21 levels tended to be associated with less pericardial fat accumulation over time, however 
the change in pericardial fat volume was very modest and could be due to measurement error. Further studies are 
needed to elucidate the longitudinal relationship of baseline FGF21 levels with pericardial fat accumulation and 
clarify the physiological role of FGF21 in pericardial fat accumulation.
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